Donghui Zhou
About Donghui Zhou
Donghui Zhou is a Senior Manager of Statistical Programming at Mirati Therapeutics, where he has worked since 2022. He has over 15 years of experience in statistical programming, primarily in oncology, and holds multiple degrees in engineering, chemistry, and biostatistics.
Work at Mirati Therapeutics
Donghui Zhou has been serving as Senior Manager of Statistical Programming at Mirati Therapeutics since 2022. In this role, Zhou is responsible for overseeing statistical programming activities, contributing to the development of oncology therapies. The position is based in San Diego, California, where Zhou applies extensive programming expertise to support clinical trials and regulatory submissions.
Previous Experience in Statistical Programming
Before joining Mirati Therapeutics, Donghui Zhou held several significant positions in the field of statistical programming. Zhou worked at Nektar Therapeutics as Lead Statistical Programmer from 2017 to 2022. Prior to that, Zhou was a Lead Statistical Programmer at Eisai US from 2014 to 2017. Zhou also served as Principal SAS Programmer at Forest Laboratories from 2007 to 2014, accumulating a total of 15 years of experience in statistical programming.
Education and Expertise
Donghui Zhou holds a Bachelor of Engineering in Chemical Engineering from Hefei University of Technology. Zhou furthered education by obtaining a Master of Science in Biostatistics from Rutgers University and a Master's degree in Chemistry from the University of Cincinnati. This educational background supports Zhou's extensive knowledge in statistical methodologies and programming, particularly in oncology.
Statistical Programming Skills and Knowledge
With 15 years of hands-on experience in statistical programming, Donghui Zhou possesses in-depth knowledge of CDISC standards, including ADaM and SDTM. Zhou has focused the last eight years on oncology-related projects, demonstrating expertise in managing contract research organizations (CROs) and experience with NDA submissions, which are critical for regulatory processes in the pharmaceutical industry.